220 related articles for article (PubMed ID: 32409690)
1. TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition.
Bamezai S; Demir D; Pulikkottil AJ; Ciccarone F; Fischbein E; Sinha A; Borga C; Te Kronnie G; Meyer LH; Mohr F; Götze M; Caiafa P; Debatin KM; Döhner K; Döhner H; González-Menéndez I; Quintanilla-Fend L; Herold T; Jeremias I; Feuring-Buske M; Buske C; Rawat VPS
Leukemia; 2021 Feb; 35(2):389-403. PubMed ID: 32409690
[TBL] [Abstract][Full Text] [Related]
2. MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL.
Poole CJ; Lodh A; Choi JH; van Riggelen J
Epigenetics Chromatin; 2019 Jul; 12(1):41. PubMed ID: 31266538
[TBL] [Abstract][Full Text] [Related]
3. Direct inhibition of dioxygenases TET1 by the rheumatoid arthritis drug auranofin selectively induces cancer cell death in T-ALL.
Chen L; Ren A; Zhao Y; Chen H; Wu Q; Zheng M; Zhang Z; Zhang T; Zhong W; Lin J; Zhu H
J Hematol Oncol; 2023 Nov; 16(1):113. PubMed ID: 37993905
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribosyl)ation is involved in the epigenetic control of TET1 gene transcription.
Ciccarone F; Valentini E; Bacalini MG; Zampieri M; Calabrese R; Guastafierro T; Mariano G; Reale A; Franceschi C; Caiafa P
Oncotarget; 2014 Nov; 5(21):10356-67. PubMed ID: 24939750
[TBL] [Abstract][Full Text] [Related]
5. Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
Piao J; Takai S; Kamiya T; Inukai T; Sugita K; Ohyashiki K; Delia D; Masutani M; Mizutani S; Takagi M
Cancer Lett; 2017 Feb; 386():131-140. PubMed ID: 27894958
[TBL] [Abstract][Full Text] [Related]
6. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
7. Chronic ethanol-mediated hepatocyte apoptosis links to decreased TET1 and 5-hydroxymethylcytosine formation.
Ji C; Nagaoka K; Zou J; Casulli S; Lu S; Cao KY; Zhang H; Iwagami Y; Carlson RI; Brooks K; Lawrence J; Mueller W; Wands JR; Huang CK
FASEB J; 2019 Feb; 33(2):1824-1835. PubMed ID: 30188753
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
9. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Ma L; Bian X; Lin W
J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
[TBL] [Abstract][Full Text] [Related]
10. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
12. Ten-eleven translocation protein 1 modulates medulloblastoma progression.
Kim H; Kang Y; Li Y; Chen L; Lin L; Johnson ND; Zhu D; Robinson MH; McSwain L; Barwick BG; Yuan X; Liao X; Zhao J; Zhang Z; Shu Q; Chen J; Allen EG; Kenney AM; Castellino RC; Van Meir EG; Conneely KN; Vertino PM; Jin P; Li J
Genome Biol; 2021 Apr; 22(1):125. PubMed ID: 33926529
[TBL] [Abstract][Full Text] [Related]
13. Decrease of 5hmC in gastric cancers is associated with TET1 silencing due to with DNA methylation and bivalent histone marks at TET1 CpG island 3'-shore.
Park JL; Kim HJ; Seo EH; Kwon OH; Lim B; Kim M; Kim SY; Song KS; Kang GH; Kim HJ; Choi BY; Kim YS
Oncotarget; 2015 Nov; 6(35):37647-62. PubMed ID: 26462176
[TBL] [Abstract][Full Text] [Related]
14. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
[TBL] [Abstract][Full Text] [Related]
15. Loss of TET1 facilitates DLD1 colon cancer cell migration via H3K27me3-mediated down-regulation of E-cadherin.
Zhou Z; Zhang HS; Liu Y; Zhang ZG; Du GY; Li H; Yu XY; Huang YH
J Cell Physiol; 2018 Feb; 233(2):1359-1369. PubMed ID: 28513825
[TBL] [Abstract][Full Text] [Related]
16. Role of TET1-mediated epigenetic modulation in Alzheimer's disease.
Armstrong MJ; Jin Y; Vattathil SM; Huang Y; Schroeder JP; Bennet DA; Qin ZS; Wingo TS; Jin P
Neurobiol Dis; 2023 Sep; 185():106257. PubMed ID: 37562656
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
Li L; Karanika S; Yang G; Wang J; Park S; Broom BM; Manyam GC; Wu W; Luo Y; Basourakos S; Song JH; Gallick GE; Karantanos T; Korentzelos D; Azad AK; Kim J; Corn PG; Aparicio AM; Logothetis CJ; Troncoso P; Heffernan T; Toniatti C; Lee HS; Lee JS; Zuo X; Chang W; Yin J; Thompson TC
Sci Signal; 2017 May; 10(480):. PubMed ID: 28536297
[TBL] [Abstract][Full Text] [Related]
18. PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice.
Ghonim MA; Pyakurel K; Ibba SV; Wang J; Rodriguez P; Al-Khami AA; Lammi MR; Kim H; Zea AH; Davis C; Okpechi S; Wyczechowska D; Al-Ghareeb K; Mansy MS; Ochoa A; Naura AS; Boulares AH
Clin Sci (Lond); 2015 Dec; 129(11):951-62. PubMed ID: 26205779
[TBL] [Abstract][Full Text] [Related]
19. A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin.
Arena S; Corti G; Durinikova E; Montone M; Reilly NM; Russo M; Lorenzato A; Arcella P; Lazzari L; Rospo G; Pagani M; Cancelliere C; Negrino C; Isella C; Bartolini A; Cassingena A; Amatu A; Mauri G; Sartore-Bianchi A; Mittica G; Medico E; Marsoni S; Linnebacher M; Abrignani S; Siena S; Di Nicolantonio F; Bardelli A
Clin Cancer Res; 2020 Mar; 26(6):1372-1384. PubMed ID: 31831554
[TBL] [Abstract][Full Text] [Related]
20. MAPK4 deletion enhances radiation effects and triggers synergistic lethality with simultaneous PARP1 inhibition in cervical cancer.
Tian S; Lou L; Tian M; Lu G; Tian J; Chen X
J Exp Clin Cancer Res; 2020 Jul; 39(1):143. PubMed ID: 32711558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
